For help on how to get the results you want, see our search tips.
3 results
Medicine
Referrals Remove Referrals filter
Orphan designations Remove Orphan designations filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Additional monitoring Remove Additional monitoring filter
Accelerated assessment Remove Accelerated assessment filter
Referral status
European Commission final decision Remove European Commission final decision filter
Procedure started Remove Procedure started filter
Referral type
Article 20 procedures Remove Article 20 procedures filter
Article 31 referrals Remove Article 31 referrals filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Quinolone- and fluoroquinolone-containing medicinal products
nalidixic acid, pipemidic acid, cinoxacin, enoxacin, pefloxacin, lomefloxacin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, prulifloxacin, rufloxacin, flumequin, associated names: Quinsair, Article 31 referrals
Status: European Commission final decision, opinion/position date: 15/11/2018, EC decision date: 11/03/2019, Last updated: 08/06/2023 -
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020